XML 49 R40.htm IDEA: XBRL DOCUMENT
v3.19.2

Deferred Revenue - Additional Information (Detail) $ / shares in Units, € in Thousands, $ in Thousands, shares in Millions |  |  | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Feb. 28, 2017 EUR (€) | Feb. 28, 2017 USD ($) | Dec. 20, 2016 EUR (€) $ / shares | Jan. 31, 2017 USD ($) | Jun. 30, 2019 EUR (€) shares | Mar. 31, 2019 EUR (€) | Mar. 31, 2019 USD ($) | Jun. 30, 2019 EUR (€) shares | Jun. 30, 2019 USD ($) $ / shares | Jun. 30, 2018 EUR (€) | Dec. 31, 2018 USD ($) | Jun. 30, 2019 USD ($) shares | Dec. 31, 2018 EUR (€) | Dec. 20, 2016 USD ($)
Disclosure of deferred income [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total deferred revenue |  |  |  |  | € 106,874 |  |  | € 106,874 |  |  |  |  | € 114,609 |
Aggregate purchase price |  |  |  |  |  |  |  | 1 |  | € 44,731 |  |  |  |
Revenue recognized |  |  |  |  | 100 |  |  | 200 |  |  |  |  |  |
Upfront and Milestone Payments [member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of deferred income [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  | 200 |  |  | 500 |  |  |  |  |  |
Incyte Corporation [member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of deferred income [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable upfront payment receivable |  |  |  |  | € 112,000 |  |  | € 112,000 |  |  |  | $ 120,000 |  |
Common shares issued | shares |  |  |  |  | 3.2 |  |  | 3.2 |  |  |  | 3.2 |  |
Purchase price per share | $ / shares |  |  |  |  |  |  |  |  | $ 25.00 |  |  |  |  |
Aggregate purchase price | $ |  |  |  | $ 80,000 |  |  |  |  |  |  |  |  |  |
Non-refundable upfront payment | € 112,000 | $ 120,000 |  |  |  |  |  |  |  |  |  |  |  |
Incyte collaboration agreement [member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of deferred income [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total deferred revenue |  |  |  |  | € 104,700 |  |  | € 104,700 |  |  |  |  | 112,600 |
Non-refundable upfront payment |  |  |  |  |  |  |  | 112,000 | $ 120,000 |  |  |  |  |
Consideration from the issuance and sale of common shares |  |  |  |  |  |  |  | 143,400 | 152,600 |  |  |  |  |
Simcere collaboration and license agreement [member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of deferred income [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total deferred revenue |  |  |  |  | 1,600 |  |  | 1,600 |  |  |  |  | € 2,100 |
Non-refundable upfront payment |  |  |  |  |  |  |  | 2,300 | 2,750 |  |  |  |  |
Milestone payments |  |  |  |  |  |  |  | 600 | 800 |  |  |  |  |
Betta collaboration and license agreement [member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of deferred income [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total deferred revenue |  |  |  |  | € 600 |  |  | 600 |  |  |  |  |  |
ONO Research and License Agreement [member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of deferred income [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Performance obligation recognized as revenue | $ |  |  |  |  |  |  |  |  |  |  | $ 1,200 |  |  |
Paid for full time equivalent funding |  |  |  |  |  |  |  | 200 |  |  |  |  |  |
Compensate for research service |  |  |  |  |  |  |  | 300 |  |  |  |  |  |
ONO Research and License Agreement [member] | Deferred revenue [member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of deferred income [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable upfront payment |  |  |  |  |  |  |  | 700 |  |  |  |  |  |
Incyte share subscription agreement [member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of deferred income [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total deferred revenue |  |  | € 31,400 |  |  |  |  |  |  |  |  |  |  | $ 32,600
Purchase price per common share | $ / shares |  |  | € 25.00 |  |  |  |  |  |  |  |  |  |  |
Consideration from the issuance and sale of common shares |  |  |  |  |  |  |  | 31,400 | 32,600 |  |  |  |  |
Betta Pharmaceuticals Co Ltd [member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of deferred income [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable upfront payment |  |  |  |  |  | € 900 | $ 1,000 |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  | € 10,500 | $ 12,000 | € 10,500 | $ 12,000 |  |  |  |  |

X
- Definition The amount of consideration paid or received in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Subsidiaries [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 7 -IssueDate 2018-01-01 -Paragraph 40 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&num=7&date=2018-03-01&anchor=para_40_a&doctype=Standard -URIDate 2018-03-16 + Details
Name: | ifrs-full_ConsiderationPaidReceived
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of liability representing income that has been received but is not yet earned. [Refer: Revenue] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2018-01-01 -Paragraph 78 -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&num=1&date=2018-03-01&anchor=para_78&doctype=Standard -URIDate 2018-03-16 + Details
Name: | ifrs-full_DeferredIncome
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The number of shares issued by the entity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2018-01-01 -Paragraph 106 -Subparagraph d -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&num=1&date=2018-03-01&anchor=para_106_d&doctype=Standard -URIDate 2018-03-16 + Details
Name: | ifrs-full_NumberOfSharesIssued
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash inflow from issuing shares. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 7 -IssueDate 2018-01-01 -Paragraph 17 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&num=7&date=2018-03-01&anchor=para_17_a&doctype=Standard -URIDate 2018-03-16 + Details
Name: | ifrs-full_ProceedsFromIssuingShares
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount paid for full time equivalent funding. + References No definition available. + Details
Name: | mrus_AmountPaidForFullTimeEquivalentFunding
Namespace Prefix: | mrus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount paid to compensate for research services. + References No definition available. + Details
Name: | mrus_AmountPaidToCompensateForResearchServices
Namespace Prefix: | mrus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Disclosure of deferred income. + References No definition available. + Details
Name: | mrus_DisclosureOfDeferredIncomeLineItems
Namespace Prefix: | mrus_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone Payment Received. + References No definition available. + Details
Name: | mrus_MilestonePaymentReceived
Namespace Prefix: | mrus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Non-refundable upfront payments receivable. + References No definition available. + Details
Name: | mrus_NonRefundableUpfrontPaymentsReceivable
Namespace Prefix: | mrus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Purchase price per common share. + References No definition available. + Details
Name: | mrus_PurchasePricePerCommonShare
Namespace Prefix: | mrus_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue recognized + References No definition available. + Details
Name: | mrus_RevenueRecognized
Namespace Prefix: | mrus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue remaining performance obligations. + References No definition available. + Details
Name: | mrus_RevenueRemainingPerformanceObligations
Namespace Prefix: | mrus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Share purchased price per share. + References No definition available. + Details
Name: | mrus_SharePurchasedPricePerShare
Namespace Prefix: | mrus_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront payment + References No definition available. + Details
Name: | mrus_UpfrontPayment
Namespace Prefix: | mrus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=mrus_UpfrontAndMilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_IncyteCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfContractsAxis=mrus_IncyteCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfContractsAxis=mrus_SimcereCollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfContractsAxis=mrus_BettaCollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfContractsAxis=mrus_OnoResearchAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=mrus_DeferredRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfContractsAxis=mrus_IncyteShareSubscriptionAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfContractsAxis=mrus_BettaPharmaceuticalsCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |